Avenue Therapeutics (ATXI) Q3 2025 earnings summary

Executive summary

• Net loss for the nine months ended September 30, 2025, was $2.2 million, a significant improvement from $10.1 million in the prior year period, mainly due to reduced R&D expenses after the sale of AJ201 and BAER-101 programs.

• The company recognized $1.4 million in revenue from the termination and transfer of the AnnJi license agreement.

• Nasdaq delisted the company's common stock in March 2025; shares now trade on the OTC market, impacting liquidity and access to capital.

• Sale of Baergic subsidiary to Axsome in November 2025 for $0.3 million upfront and potential future milestone and royalty payments.

Financial highlights

• Cash and cash equivalents were $3.7 million as of September 30, 2025, up from $2.6 million at year-end 2024.

• Operating expenses for the quarter dropped 77% year-over-year to $0.7 million, driven by lower R&D and G&A costs.

• R&D expenses for the nine months ended September 30, 2025, were $0.8 million, down from $6.1 million in the prior year period.

• General and administrative expenses for the nine months were $3.0 million, down from $3.6 million year-over-year.

• Net cash used in operating activities was $1.0 million for the nine months, with $2.1 million provided by financing activities.

Outlook and guidance

• The company expects continued operating losses and will require additional financing to fund ongoing development, particularly for the planned Phase 3 IV tramadol safety study.

• Initiation of the IV tramadol safety study is contingent on securing necessary funding or partnership.